New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called Fabry disease. In this case certain fat molecules are not digested and broken down by the body - but remain in the cells. These fat molecules build up to dangerous levels, which start to damage the body, because they accumulate e.g. in the walls of the blood vessels. This accumulation in the blood vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a stroke. The purpose of this study is to investigate the stroke rehabilitation of Fabry patients during different therapeutic standard approaches for stroke and for Fabry disease (if any). During this study, stroke patients with Fabry disease will be monitored in greater detail to determine whether the differences in treatment are significant for patient recovery and on what they depend.
In a group of young stroke patients with diagnosed Fabry disease the stroke rehabilitation will be investigated during different prophylactic therapeutic approaches. In this study the investigator will not be given any instructions on stroke and Fabry therapy. All patients with any etiology of stroke and a diagnosed Fabry disease submitted to the stroke unit of the participating centres which commit to work with the EUSI (European Stroke Initiative) recommendations for stroke management and diagnosis will be included into the study.
Study Type
OBSERVATIONAL
Enrollment
100
Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
Universitätsklinikum für Neurologie
Graz, Austria
Department of Neurology, University Hospital Sestre Milosrdnice
Zagreb, Croatia
Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires
Lyon, France
Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university
Tbilisi, Georgia
Department of Neurology, Klinikum Hohe Warte
Bayreuth, Germany
Charite Campus Benjamin Franklin, Dept. of Neurology
Berlin, Germany
Department of Neurology, Allgemeines Krankenhaus Celle
Celle, Germany
Department of Neurology, Klinikum Chemnitz gGmbH
Chemnitz, Germany
Department of Neurology, Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
Heinrich-Heine-University Duesseldorf, Dept. of Neurology
Düsseldorf, Germany
...and 10 more locations
Determination of the relapse rate of acute cerebrovascular events with clinical relevance in patients with different prophylactic approaches
Time frame: 54 months study duration
Quality of Life measured with the SF-36
Time frame: 54 months study duration
Number of acute CVEs without clinical significance but with obvious signs in MRI diagnosis
Time frame: 54 months study duration
Beck Depression Inventory II (BDI II)
Time frame: 54 months study duration
Brief Pain Inventory (BPI)
Time frame: 54 months study duration
Rostocker Kopfschmerzfragen-Komplex (RoKoKo) (only in Austria and Germany)
Time frame: 54 months study period
Habi test (only in Austrian and German centers)
Time frame: 54 months study duration
Trail Making Test (TMT)
Time frame: 54 months study duration
Functional neurological deficits measured by the Mini Mental State Examination (MMSE)
Time frame: 54 months study duration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.